Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (UNAUDITED)

v3.8.0.1
CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (UNAUDITED) - 3 months ended Jan. 31, 2018 - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total Shareholders' Equity [Member]
Noncontrolling Interest [Member]
Total
Balance, October 31, 2017 at Oct. 31, 2017 $ 166,028 $ 163,931,079 $ (156,174,184) $ 7,922,923   $ 7,922,923
Balance, October 31, 2017 (in Shares) at Oct. 31, 2017 16,602,759          
Stock option compensation to employees and directors   214,427   214,427   214,427
Stock option compensation to consultants   52,546   52,546   52,546
Common stock issued upon exercise of stock options $ 231 (231)        
Common stock issued upon exercise of stock options (in Shares) 23,085          
Common stock issued to consultants $ 53 14,949   15,002   15,002
Common stock issued to consultants (in Shares) 5,347          
Issuance of noncontrolling interest in Certainty Therapeutics, Inc   68,974   68,974 $ (4,318) 64,656
Net loss     (1,838,072) (1,838,072) (27,402) (1,865,474)
Balance, January 31, 2018 at Jan. 31, 2018 $ 166,312 $ 164,281,744 $ (158,012,256) $ 6,435,800 $ (31,720) $ 6,404,080
Balance, January 31, 2018 (in Shares) at Jan. 31, 2018 16,631,191